Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead To Let Kite Fly Free; O’Day Says It Will Become Separate Business Unit

Executive Summary

On his first earnings call, the new CEO said he wanted to make a quick decision on Kite, which will have its own CEO and autonomy. The unit's Yescarta posted 19% sequential revenue growth.

You may also be interested in...



Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma

Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.

Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy

Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.

Gilead Writes Down Kite Buy As Yescarta Sales Flatten Out

Gilead takes $800m impairment charge against Kite acquisition a year after an $820m write-down. Kite and Yescarta are appear to be afterthoughts in discussions of Gilead’s portfolio and pipeline.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC125163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel